MedWatch

Leo challenges Novartis with tablet agreement

Leo Pharma has signed a global licensing agreement for a new candidate. It will be the company's first tablet therapy against atopic dermatitis and a possible rival to a drug from Novatis.

Foto: Leo Pharma PR

With a new licensing agreement with South Korean JW Pharmaceuticals, Leo Pharma has got a hold on a candidate drug in the very early stages.

The candidate JW1601 will only enter the clinical phase I by the end of this year. Nevertheless, Leo Pharma's Executive Vice President, Global Research & Development, Kim Kjøller, has high hopes for the drug - especially as it will be the Danish company's first tablet therapy against atopic dermatitis if it enters the market.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier